Genentech has doubled its initial investment in a new manufacturing facility located in Holly Springs, North Carolina, bringing investment in the project to around $2bn.
The facility is the first established by Genentech on the US East Coast. The company announced its initial investment in May 2025, followed with an announcement in August that year that it had broken ground on the project.
It is expected that the newly expanded facility, which is set to be operational in 2029, will bring in 100 jobs for North Carolina’s economy. The facility will support over 500 high-wage manufacturing jobs, as well as 1,500 construction jobs. The expansion of Genentech’s investment in the area will bring a major increase in output. The Holly Springs facility will produce treatments for metabolic conditions, including obesity, and Genentech aims to drive efficiency through the use of advanced biomanufacturing and automation systems.
Holly Springs was chosen for the project due to its skilled local workforce and proximity to both academic institutions and life sciences companies.
The expansion builds on Roche and Genentech’s previously-announced $50bn US manufacturing investment commitment. The two companies currently have 13 manufacturing sites and 15 R&D sites across eight US states, employing a staff of 25,000.
Ashley Magargee, CEO of Genentech, said: “This expansion reflects our long-term commitment to the United States. This additional investment will create more high-quality jobs, strengthen local partnerships and ensure a resilient supply of medicines for years to come, allowing us to bring life-changing medicines to patients faster and more reliably.”